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Abstract. Rearrangement and amplification of the 
D-type cyclin genes have been reported in human cancer. 
Previous studies have demonstrated that Ras-mediated skin 
tumorigene sis depends on pathways that act through cyclin 
D1 and D2; however, the role of cyclin D3 remains unknown. 
The present study demonstrates that cyclin D3 ablation does 
not affect keratinocyte proliferation, but instead increases 
apoptosis levels in the bulge region of the hair follicle. 
Consequently, cyclin D3 ablation reduces skin papilloma 
development in a Ras-dependent carcinogenesis model. 
Previous results revealed that cyclin D3 preferentially binds 
to cyclin-dependent kinase 6 (CDK6) in mouse keratinocytes 
and transgenic expression of CDK6 (K5CDK6 mice) inhibits 
skin tumor development. Thus, we hypothesized that the 
inhibitory effect of CDK6 is dependent on cyclin D3 expres-
sion. To test this hypothesis, a mouse model that overexpresses 
CDK6 and does not express cyclin D3 (K5CDK6/cyclin 
D3-/- compound mouse) was developed. Biochemical analysis 
of the epidermis of K5CDK6/cyclin D3-/- mice revealed 
that cyclin D3 ablation resulted in increased expression of 
cyclin D1 protein, with a consequent elevation in the level 
of CDK6/cyclin D1 and CDK4/cyclin D1 complexes. These 
findings were concurrent with the increase skin papilloma 
malignant progression observed in K5CDK6/cyclin D3-/- mice. 
In summary the absence of cyclin D3 led to fewer number of 
papillomas in cyclin D3-ablated mice than in the wild-type 
owing to increased apoptosis, suggesting that alterations in 
cell survival are a crucial mechanism for crippling cellular 
defense against neoplasia. The results of the current study 
also suggest that although cyclin D3 expression does not alter 
the tumor suppressive role of CDK6 in skin carcinogenesis, 
the compensatory increase in cyclin D1 can shift the balance 
towards malignant progression.
Introduction
Cell growth and differentiation require accurate control of 
the mechanism regulating the entry into, passage through, 
and withdrawal from the cell cycle. Progress through the G1 
phase of the cell cycle is mediated by the D-type cyclin family, 
which are key regulators of the cyclin-dependent kinases 
(CDKs) 4 and 6 (1,2). D-type cyclins/CDK complexes are key 
cell-cycle regulators, which phosphorylate critical substrates 
for cell-cycle progression, including the retinoblastoma (pRb) 
family of proteins (3-6). Therefore, CDK4, CDK6 and D-type 
cyclins serve as master integrators in the G1 phase and couple 
with cell cycle mitogenic signals to mediate their onco-
genic properties in cancer cells (6-8). The highly conserved 
sequence among the three D-type cyclins suggests that they 
serve redundant roles. However, each member is expressed 
in a tissue‑specific manner (1,9). Consistent with their role 
in cell proliferation, abnormal levels of D-type cyclins have 
been associated in the development of various types of human 
cancer. The rearrangement and/or amplification of the cyclin 
D1 gene has been widely reported in a range of human cancers, 
including carcinoma of the uterine cervix, breast carcinomas, 
and head and neck squamous cell carcinomas (10-12). 
Likewise, overexpression of the cyclin D2 gene have been 
documented in testicular tumors (13,14) and B-cell malignan-
cies (15). The deregulated expression of cyclin D3 has also been 
described in several types of human cancer (16-19), including 
malignancies of the thymus (20). Consistent with these results, 
Sicinska et al (21) reported that mice deficient in cyclin D3 
exhibited specific defects in T-lymphocyte development. 
Previous studies have employed the mouse skin model to study 
the role of D-type cyclins in normal and neoplastic prolifera-
tion (22-26). These studies revealed that cyclin D1 and D2 are 
overexpressed in mouse skin papillomas and squamous-cell 
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carcinomas (SCC), whereas levels of cyclin D3 protein remain 
constant in skin tumors (27). Previous studies have demon-
strated that Ras-mediated skin tumorigenesis is dependent on 
pathways that signal preferentially through cyclin D1 and D2. 
Consistent with this idea, it was demonstrated that ablation of 
cyclin D1 or cyclin D2 led to the developmental inhibition of 
mouse skin papilloma (28,29). Currently, the role of cyclin D3 
in skin tumorigenesis remains poorly understood.
The present study investigated the effect of the genetic 
modification of cyclin D3 and CDK6 in skin carcinogenesis 
and normal keratinocyte proliferation. A number of previous 
studies by the present authors and the others have used the 
two-stage skin carcinogenesis protocol, which is a well-suited 
model for understanding the multistage nature of tumor 
progression in order to validate the importance of tumor 
suppressors and oncogenes in skin cancer formation and 
transformation (28-41). In this model of chemically induced 
skin tumorigenesis, tumor initiation is accomplished via a 
single topical application of a genotoxic carcinogen, including 
7,12-dimethylbenz(a)anthracene (DMBA), which produces a 
heritable mutation in the Ha-Ras oncogene. Tumor promo-
tion is induce via multiple applications of a tumor promoter, 
usually 12-O-tetradecanoylphorbol-13-acetate (TPA), leading 
to the expansion of the initiated cells. TPA induces the hyper-
proliferation of cells, which promotes the generation of benign 
tumors, or papillomas, which can, in certain cases, progress to 
SCC (malignant progression). In the mouse epidermis, cyclin 
D3 preferentially binds to CDK6 and, although counterintui-
tive, overexpression of CDK6 leads to inhibition of mouse skin 
tumorigenesis (27,36). The authors have hypothesized that the 
tumor-inhibitory role of CDK6 depends largely on binding 
to cyclin D3. In the present study, cyclin D3‑deficient mice 
were used to investigate the role of cyclin D3 in skin tumorige-
nesis. Compound mice overexpressing CDK6 in the absence 
of cyclin D3 were also assessed to determine the effect of 
cyclin D3 ablation in CDK6-dependent skin tumor develop-
ment. The present study demonstrated that cyclin D3 deficiency 
reduces the number of benign skin tumors (papillomas) due 
to increased apoptosis in the hair follicle but does not alter 
normal keratinocyte proliferation. Although cyclin D3 binds 
preferentially to CDK6 (27), the tumor inhibition media ted 
by CDK6 is independent of cyclin D3. Finally, the present 
study revealed that modification in the D-type cyclin and 
CDK levels resulted in unbalanced formation of CDK/cyclin 
complexes leading to reduced papilloma development, but to a 
more aggressive tumor phenotype.
Materials and methods
Mouse models. The cyclin D3-knockout mice were provided 
by Dr Peter Sicinski, Department of Genetics, Harvard 
Medical School (Boston, MA, USA) (21), and the generation 
of K5CDK6 transgenic mice was as previously reported (36). 
Cyclin D3+/- mice were backcrossed with the FVB genetic 
background (The Jackson Lab, Bar Harbor, ME, USA) for 
three generations to reduce the influence of the genetic back-
ground. K5CDK6 mice were mated with cyclin D3+/- mice 
to obtain K5CDK6/cyclin D3+/- mice and backcrossed with 
cyclin D3+/- mice to acquire K5CDK6/cyclin D3-/- mice. The 
mice were housing at the animal facility of the College of 
Veterinary Medicine, NC State University. Housing conditions 
include a 12 h light/dark cycle, 20‑23˚C and water and food 
were accessible at all times. The genotype of the mice was 
confirmed by polymerase chain reaction (PCR) as previou sly 
described (21,36) using KAPA2G fast PCR kit (Kapa Biosys-
tems, Inc., Wilmington, MA, USA).
Mouse experiments. The animal research protocols were 
approved by the Institutional Animal Care and Use Committee 
at North Carolina State University (Raleigh, NC, USA). The 
end-point of the two-stage carcinogenesis experiments was 
the quantification of the number of skin tumors developed 
during a 20-25 weeks period or an individual skin tumor size 
of 1,800 mm3, at which point the animal would have reached 
the study end-point. Tumor burden may exceed 1,800 mm3 
when multiple tumors are present but no individual tumor 
exceeded this dimension (tumor burden did not exceed 10% 
of mouse body weight). The effect of lack of cyclin D3 in skin 
tumorigenesis was determined with 15 female mice from each 
group (wild-type vs. cyclin D3-/-). No phenotypical differe-
nces were observed between wild type and cyclin D3-/- mice. 
Three-weeks-old mice were administered with a single topical 
application of 200 nmol DMBA (Cat D3254; Sigma-Aldrich; 
Merck KGaA, Darmstadt, Germany) in 200 µl acetone on 
the dorsal surface of the mice. After 2 weeks, the mice were 
dosed topically twice a week with 4 µg TPA (Cat P1680; 
Sigma-Aldrich; Merck KGaA) in 200 µl acetone for 20 weeks. 
Papilloma development was traced weekly until the end of the 
experiment at 20 weeks. Tumors ≥1 mm in size were counted 
weekly, and the multiplicity (mean number of tumors per 
mouse) and incidence of tumor-bearing mice were compared 
between the two groups using Fisher's exact test.
To determine the effect of cyclin D3 ablation on K5CDK6 
transgenic mice, four groups of 10 mice each were utilized 
(wild-type, K5CDK6, cyclin D3-/- and K5CDK6/cyclin 
D3-/- mice). K5CDK6 mice were generated in C57BL/6 back-
ground (36) and crossed with cyclin D3-/- as aforementioned. 
Tumorigenesis in newborn mice was initiated at day 3 after 
birth with a single application of 50 µg DMBA in 50 µl acetone 
on the dorsal skin. After 3 weeks, the mice were administered 
twice a week with 4 µg TPA in 200 µl acetone for 25 weeks. 
Papilloma development was traced weekly until the end of the 
experiment at 25 weeks after the first application of the tumor 
promoter TPA. Tumors ≥1 mm in size were counted weekly 
and the multiplicity and incidence of tumor-bearing mice were 
compared between the groups using Fisher's exact test.
The mice were sacrificed by CO2 asphyxiation, and the 
dorsal skins were treated with a commercial available depila-
tory agent (Nair) for 1 min.
Western blotting and co‑immunoprecipitation assays. The 
epidermal tissue was scraped off with a razor blade, placed 
into the homogenization buffer (50 mmol/l HEPES, pH 7.5, 
150 mmol/l NaCl, 2.5 mmol/l EGTA, 1 mmol/l ethylenedi-
aminetetraacetic acid, 0.1% Tween-20, 1 mmol/l dithiothreitol, 
0.1 mmol/l phennylmethyl sulfonyl fluoride, 0.2 U/ml apro-
tinin, 10 mmol/l b-glycerophosphate, 0.1 mmol/l sodium 
vanadate and 1 mmol NaF), and homogenized using a manual 
homogenizer. The epidermal homogenate was centrifuged at 
11,000 x g for 20 min at 4˚C to collect the supernatant, which 
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was used directly for western blot analysis or stored at ‑80˚C. 
Protein concentration was measured using the Bio-Rad Protein 
Assay system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). 
Protein lysates (25 µg from each sample) were electrophoresed 
on 10% acrylamide gels and electrophoretically transferred 
onto nitrocellulose membranes. After being blocked with 
5% nonfat powdered milk in Dulbecco phosphate-buffered 
saline, the membranes were incubated with 1 µg/ml specific 
antibodies. The following antibodies were used: Polyclonal 
antibodies against cyclin D1 (sc-717), cyclin D2 (sc-593), 
CDK4 (sc-260), CDK6 (sc-177) and β-actin (sc-1616), (all from 
Santa Cruz Biotechnology, Inc., Dallas, TX, USA; all 1:100) 
and mouse monoclonal antibody against cyclin D3 (DCS-22) 
(NeoMarkers; Thermo Fisher Scientific Inc., Waltham, MA, 
USA). The membranes were washed 3-times on PBS and 
Triton X-100 (Sigma-Aldrich; Merck KGaA) and incubated 
with secondary antibodies: Goat anti-rabbit-HRP (horseradish 
peroxidase) (cat. no. sc-2020) (Santa Cruz Biotechnology, 
Inc.) or goat anti-mouse-HRP (cat. no. 31430) (Pierce; Thermo 
Fisher Scientific Inc.) and visualized using enhanced chemilu-
minescence (ECL detection kit; GE Healthcare Bio-Sciences, 
Pittsburgh, PA, USA).
To investigate CDK/D-type cyclin complex formations, 
5 µg of antibodies against CDK4 (100 µg/ml; cat. no. sc-260), 
CDK6 (100 µg/ml; cat. no. sc-177) and 5 µg of normal rabbit 
IgG (200 µg/ml; cat. no. sc-2027; Santa Cruz Biotechnology, 
Inc.), conjugated with protein A-sepharose beads (Thermo 
Fisher Scientific, Inc.) or Dynabeads® Protein G (Invitrogen; 
Thermo Fisher Scientific, Inc.) were used. Fresh protein lysates 
from epidermal tissue (250 µg) were immunoprecipitated for 
1 h at 4˚C with constant rotation. Following three washes with 
extraction buffer, proteins that co-immunoprecipitated were 
analyzed by western blot analysis as aforementioned. Protein 
lysate (25 µg) was loaded as a control input.
Immunostaining. Epithelial cell proliferation was measured 
by intraperitoneal injection of 60 µg/g 5-bromodeoxyuri-
dine (BrdU) 30 min prior to the sacrifice of mice by CO2 
asphyxiation. Dorsal skin and tumor sections were fixed in 
10% formalin (Cat. HT5014; Sigma-Aldrich; Merck KGaA) at 
room temperature for 48 h and embedded in paraffin prior to 
sectioning. Tissue sections (thickness, 4 µm) were stained with 
hematoxylin and eosin (H&E) for 5 min at room temperature 
and were used for histopathological analysis.
BrdU incorporation was detected by immunohistochemical 
staining of paraffin‑embedded skin and tumor sections with a 
mouse anti-BrdU (S7101) monoclonal antibody (Calbiochem; 
EMD Millipore, Billerica, MA, USA), biotin-conjugated 
anti-mouse antibody (Vector Laboratories, Inc., Burlingame, 
CA, USA), and avidin-biotin Vectastain Elite peroxidase 
kit (Vector Laboratories, Inc.) with diaminobenzidine as a 
chromogen. Apoptotic cells were identified using terminal 
deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assays with the FragEL DNA Fragmentation Detec-
tion kit and Colorimetric-TdT enzyme (EMD Millipore), 
according to the manufacturer's instructions. Briefly, the 
terminal deoxynucleotidyl transferase (TdT enzyme) binds to 
the exposed 3'OH ends of a DNA fragment generated in apop-
tosis progression and catalyzes the addition of biotin-labeled 
and unlabeled deoxynucleotides. Biotinylated nucleotides 
were detected using a streptavidin-HRP conjugate. The slides 
were counterstained with methyl green for quantification of 
normal and apoptotic cells. The numbers of apoptotic cells 
in skin tumors were determined in 250 µm2 sections with a 
reticule grid using a light microscope (Nikon Eclipse E400). 
Apoptotic keratinocytes in interfollicular and follicular 
epidermis were quantified in sections (thickness, 2 cm). To 
determine the incidence of follicular apoptosis, hair follicles 
with ≥1 apoptotic cell in the bulge area were counted as a posi-
tive hair follicle. In all cases, 12 fields (magnification, x400) 
were counted per section in a total of 10 sections representing 
5 mice per genotype.
Statistical analysis. Statistical analysis [paired t-test, analysis 
of variance (one-way ANOVA), Bonferroni's multiple compar-
ison test and correlation Person's test) was performed using 
GraphPad Prism 4 software (GraphPad Software Inc., La 
Jolla, CA, USA). P<0.05 was considered to indicate a statisti-
cally significant difference.
Results
Reduced sensitivity to ras‑dependent skin papilloma develop‑
ment in cyclin D3‑null mice. The authors of the present study 
have previously reported that knocking out cyclin D1- and 
cyclin D2 has a mild effect on the proliferative status of mouse 
epidermis, but lead to a severe reduction in the sensitivity to the 
development of skin papillomas induced by chemical carcino-
genesis (28,42). To investigate the effect of cyclin D3 ablation 
in mouse skin, cyclin D3-null mice developed by gene targeting 
in embryonic stem cells were utilized (21). First, the authors 
investigated whether ablation of cyclin D3 affected epidermal 
homeostasis. To this end, formalin‑fixed, paraffin‑embedded 
skin cross-sections of cyclin D3-/- and wild-type siblings were 
examined. H&E-stained sections revealed no changes in the 
skin structure of cyclin D3-/- compared with wild-type mice. 
No marked alterations in the morphology of the follicular 
and interfollicular epidermis were observed between cyclin 
D3-/- and wild-type siblings (Fig. 1A and B). Consistent with 
this data, cyclin D3-/- and wild-type mice exhibit no differe-
nces in the total number of nucleated keratinocytes in the 
interfollicular epidermis. To determine whether loss of cyclin 
D3 affected epidermal homeostasis, the rate of keratinocyte 
proliferation and apoptosis was examined. Cyclin D3-/- mice 
did not exhibit any detectable alterations in keratinocyte 
proliferation as determined by epidermal thickness (data not 
shown) and the number of BrdU-positive cells in the interfol-
licular epidermis compared with wild-type mice (Fig. 1C-E). 
The authors conclude that epidermal keratinocytes proliferate 
normally in the absence of cyclin D3, likely through compen-
sation by other members of the D-type cyclin family.
The authors also studied whether a lack of cyclin D3 
affects apoptosis in interfollicular epidermis and hair follicles. 
As previously reported, the number of apoptotic keratino-
cytes in the interfollicular epidermis was barely affected by 
knockout of cyclin D3 (0.2%) (42-44), and no differences were 
observed between cyclin D3-/- and wild-type mice (data not 
shown). Although the hair follicle stem cells do not contribute 
to the homeostasis of mouse epidermis. It is known that stem 
cells located in the bulge area of the hair follicle participate in 
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hyperproliferative conditions, including epidermis regenera-
tion hyperproliferation conditions (45). Therefore, the number 
of hair follicles carrying apoptotic cells in the bulge region 
was quantified to determine the incidence of apoptosis in hair 
follicles. A two-fold increase was observed in the number 
of hair follicles carrying apoptotic cells in cyclin D3-/- mice 
compared with wild-type siblings (P<0.001, t-test) (Fig. 1F). 
Supporting the data of the present study, it was previously 
reported that downregulation of cyclin D3 also results in 
increased apoptosis in leukemia cells (46). Importantly, multi-
potent stem cells localized in the bulge region of the mouse hair 
follicle retain chemical carcinogens and have been hypothe-
sized as the origin of skin papillomas (47,48). Consequently, 
the authors next asked whether increased apoptosis observed 
Figure 1. Skin phenotype of cyclin D3‑null mice. Representative paraffin‑embedded sections of skin from (A) WT mice and (B) cyclin D3-/- mice stained with 
hematoxylin and eosin. BrdU labeling of sections from (C) WT and (D) cyclin D3-/- mice detected using anti‑BrdU antibody. Magnification, x400. (E) In vivo 
proliferation assay using BrdU staining in the basal cell layer of mouse epidermis. (F) Increased incidence of apoptotic cells in the bulge region of hair follicle 
from cyclin D3-/- mice compared with WT siblings (n=5, *P<0.001, t-test). BrdU, bromodeoxyuridine; KO, knockout; WT, wild-type.
Figure 2. Kinetics of cyclin D3-/- skin papilloma development. WT and cyclin D3-/- siblings were initiated with 7,12-dimethylbenz[a]anthracene and promoted 
with multiple applications of 12‑O‑tetradecanoylphorbol‑13‑acetate on dorsal mouse skin. (A) Incidence of papilloma, defined as the percentage of mice with 
≥1 papilloma, as a function of weeks of study. (B) Multiplicity, defined as the average number of papillomas per mouse, as a function of weeks of study. n=15 
for each experimental group. WT, wild-type; D3 KO, cyclin D3-/- knockout.
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throughout the bulge region of cyclin D3-/- mice would affect 
skin papilloma development. To test this hypothesis, cyclin 
D3-/- and wild-type littermates were subjected to the two-stage 
carcinogenesis protocol. This protocol induces skin papil-
lomas after a single application of a carcinogen followed by 
biweekly treatments with a tumor promoter that favors the 
selection of cells bearing Ha-ras mutations. The dorsal skin 
of cyclin D3-/- and wild-type littermates were topically treated 
with a sub-carcinogenic dose of the genotoxic DMBA, and 
tumor development was subsequently promoted via biweekly 
applications of 12-O-tetradecanoylphorbol-13-acetate (TPA) 
for 20 weeks. The incidence and multiplicity of papillomas 
were scored in each group for 20 weeks. Papilloma develop-
ment was delayed by 5 weeks in cyclin D3-null mice compared 
with wild-type siblings (Fig. 2A). The incidence of papilloma 
formation reached a plateau of 100% at 11 weeks in wild-type 
mice. By contrast, cyclin D3-/- mice reached 83% of papilloma 
incidence at 20 weeks, with ~20% of the cyclin D3-/- mice 
remaining refractory to tumor development (Fig. 2A). Tumor 
multiplicity (mean number of tumors per mice) shows a 
74% reduction in cyclin D3-/- mice compared with control 
littermates (Fig. 2B).
Collectively, these observations demonstrate that cyclin D3 
ablation does not grossly affect follicular and interfollicular 
keratinocyte proliferation, but leads to increase apoptosis in 
the bulge region of the hair follicle and decreased papilloma 
development.
Lack of cyclin D3 does not affect the tumor inhibitory 
activity of CDK6. Similar to cyclin D3 ablation, the authors 
have shown previously that transgenic expression of CDK6 
results in increased apoptosis in the hair follicle and a reduced 
number of skin papillomas in a two-stage carcinogenesis 
model (36). Notably, the authors have previously determined 
a preferential binding of cyclin D3 to CDK6 and the conse-
quent increase in CDK6/Cyclin D3 complex formation in 
hyperproliferative epidermis (49). Likewise, forced expression 
of CDK6 in epidermis of K5CDK6 transgenic mice led to 
increased binding to cyclin D3 (36). Therefore, the authors 
asked whether cyclin D3 expression is essential for the tumor 
inhibitory activity of CDK6 (36). To test this hypothesis, the 
authors developed the K5CDK6/cyclin D3-/- compound mice 
in which overexpression of CDK6 is driven by the keratin 
5 promoter (K5) to the basal cell layer of epidermis and hair 
follicles in a cyclin D3-null background. Newborn animals 
did not display any evident developmental abnormalities, and 
H&E staining of the dorsal epidermis did not reveal alterations 
in the morphology of follicular and interfollicular epidermis. 
Furthermore, no significant differences in the number of 
nucleated cells were observed in the interfollicular epidermis 
(data not shown).
To determine whether simultaneous overexpression of CDK6 
and lack of cyclin D3 affects the expression of other cell-cycle 
regulators, biochemical analysis of epidermal tissue was 
performed. Protein analysis confirmed elevated CDK6 expres-
sion and a lack of cyclin D3 in the epidermis of K5CDK6/cyclin 
D3-/- mice (Fig. 3A). Notably, a marked increase in the cyclin 
D1 protein level from cyclin D3-/- and K5CDK6/cyclin D3-/- 
epidermis compared with K5CDK6 and wild-type samples 
was observed (Fig. 3A). A mild increase in cyclin D2 protein 
expression was detected in K5CDK6 and cyclin D3-/- epidermis. 
However, this effect varied between samples.
D-type cyclins are the limiting factors during CDK/cyclin 
complex formation. Therefore, modifications in the protein 
levels of cyclin D1 may change the kinetics of complex forma-
tion in mouse epidermis (27,50). In fact, the forced expression 
of cyclin D3 in mouse epidermis resulted in elevated CDK6 
and CDK4 activity, primarily associated with increase forma-
tion of CDK4/cyclin D1, CDK6/cyclin D1 and CDK6/cyclin D3 
complexes (29). Therefore, whether transgenic expression 
of CDK6 alters D-type cyclins/CDKs complex formation 
was analyzed. Epidermal lysates from wild type, K5CDK6, 
cyclin D3-/- and K5CDK6/cyclin D3-/- mice were immunopre-
cipitated with antibodies against CDK6 and CDK4 followed 
by western blot analysis to determine associations between 
cyclin D1 and cyclin D3. In agreement with previous findings, 
it was indicated that the overexpression of CDK6 resulted in 
elevated levels of CDK6/cyclin D3 complex in the epidermis 
of K5CDK6, compared with wild-type littermates (Fig. 3B; 
Table I) (36). Expression of CDK6 was barely visible in 
the epidermis of wild-type and cyclin D3-/- mice (Fig. 3A 
and B). Consistent with the elevated protein level of cyclin 
D1, K5CDK6/cyclin D3-/- epidermis exhibited higher levels 
of CDK6/cyclin D1 complexes compared with K5CDK6 
epidermis (Fig. 3B; Table I). In addition, epidermis from 
K5CDK6/cyclin D3-/- and cyclin D3-/- mice displayed higher 
levels of CDK4/cyclin D1 complex formation compared with 
wild-type and K5CDK6 mice (Fig. 3C; Table I). These results 
confirm that, in the absence of cyclin D3, the compensatory 
increase in cyclin D1 expression leads to increased complex 
Table I. Cdk/D-type cyclin complexes in mouse epidermis.
Mouse genotype CDK6/cyclin D1 CDK6/cyclin D3 CDK4/cyclin D1 CDK4/cyclin D3
Wild-type + + + +
K5CDK6 + +++ + +
Cyclin D3-/- + - +++ -
K5CDK6/cyclin D3-/- +++ - +++ -
CDK/D-type cyclin complexes were determined by co-immunoprecipitation assays with anti-CDK4 and CDK6 antibodies and analyzed by 
western blotting with anti-D-type cyclin antibodies. CDK, cyclin-dependent kinase. (-), not determined; (+), value of CDK/cyclin complexes 
defined in wild‑type mice or less than the wild‑type value; (+++), value two‑fold or greater than wild‑type mice.
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formation with the two main CDKs of the G1 phase, CDK4 
and CDK6. Expression levels of CDK6, CDK4, and cyclin 
D1 were quantified in protein lysates (input) and immuno-
precipitated samples from K5CDK6/cyclin D3-/- and cyclin 
D3-/- mice to determine the ratio of input to immunopre-
cipitation. It was established that the majority of cyclin D1 
proteins bind to CDK4 in cyclin D3-/- and K5CDK6/cyclin 
D3-/- epidermis, whereas in wild-type and K5CDK6 epidermis 
only 12% of cyclin D1 binds to CDK4. The observation that 
CDK6 is not expressed at high levels in wild-type and cyclin 
D3-/- epidermis does not allow for verification of the ratio of 
cyclins to CDK6 complexes. The authors conclude that a lack 
of cyclin D3 lead to changes in cyclin D1 protein level, which 
favors the formation of CDK4/cyclin D1 and CDK6/cyclin 
D1 complexes in K5CDK6/D3-/- mice and CDK4/cyclin D1 
complexes in cyclin D3-/- mice. Therefore, a lack of cyclin 
Figure 4. Kinetics of cyclin K5CDK6/D3-/- skin papilloma development. WT, cyclin D3-/-, K5CDK6 and K5CDK6/cyclin D3-/- siblings were initiated with 
7,12-dimethylbenz[a]anthracene and promoted with multiple applications of 12-O-tetradecanoylphorbol-13-acetate on dorsal mouse skin. (A) Incidence of 
papilloma (percentage of mice with ≥1 papilloma) as a function of weeks of study. (B) Multiplicity (average number of papillomas per mouse) as a function of 
weeks of study. WT, wild-type; K6, K5CDK6 mice; D3, cyclin D3-/- mice; K6/D3, K5CDK6/cyclin D3-/- mice.
Figure 3. Biochemical analysis of cell cycle regulators in mouse epidermis. Epidermal lysates from WT, K6, D3 and K6/D3 mice were separated by SDS-PAGE 
and transferred onto a nitrocellulose membrane. Primary antibodies against CDK6, CDK4, cyclin D3, cyclin D2 and cyclin D1 were used for immunoblot 
analysis. β-actin was used as a loading control. (A) Epidermal lysates from WT, K6, D3 and K6/D3 mice were immunoprecipitated with antibodies against 
(B) CDK6 or (C) CDK4 and blotted with antibodies against cyclin D3, cyclin D1, CDK6 and CDK4. (D) Epidermal lysates from WT, K6, D3 and K6/D3 mice were 
loaded. CDK, cyclin-dependent kinase; K6, K5CDK6 mice; D3, cyclin D3-/- mice; K6/D3, K5CDK6/cyclinD3-/- mice WT, wild-type; IP, immunoprecipitation.
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D3 is at least partially compensated by increased cyclin D1 
protein in mouse epidermis.
In order to define whether cyclin D3 expression is essential 
for the tumor-inhibitory role of CDK6 (36), K5CDK6/cyclin 
D3-/-, K5CDK6, cyclin D3-/- and wild-type littermates were 
subjected to the two-stage carcinogenesis protocol for 25 weeks. 
The four groups developed visible papillomas between 
5-8 weeks of carcinogenic promotion (Fig. 4A). Whereas 
wild-type, K5CDK6 and K5CDK6/D3-/- mice reached 50% of 
incidence by 8-11 weeks, cyclin D3-/- mice exhibited delayed 
development of skin papillomas and reached 50% incidence 
after 15 weeks of promotion (P=0.001, t-test), remaining at 
this value until the end of the experiment. In addition, the 
incidence of papilloma formation of K5CDK6, K5CDK6/D3-/- 
and wild-type mice reached a plateau of ~80% at 13-14 weeks 
(P=0.001, t-test; Fig. 4A). As previously reported, K5CDK6 
mice display a significantly lower number of papillomas 
per mouse (multiplicity) compared with wild-type mice 
(34% reduction at 25 weeks, P=0.01, t-test; Fig. 4B)  (36). In 
support of the findings in the present study (Fig. 2B), cyclin 
D3-/- mice exhibited the strongest inhibition of papilloma 
multiplicity among the four groups (52% reduction, P=0.0002, 
t-test; Figs. 2B and 4B). Tumor inhibition of K5CDK6/cyclin 
D3-/- mice was similar to K5CDK6 mice, which displayed a 
25% reduction in multiplicity compared with wild-type mice 
(P=0.04, t-test; Fig. 4B). Importantly, papilloma incidence and 
multiplicity between K5CDK6 and K5CDK6/cyclin D3-/- mice 
showed no statistically significant differences. Therefore, 
the authors confirm that ablation of cyclin D3 causes severe 
papilloma repression (Figs. 2 and 4), but the tumor inhibition 
driven by overexpression of CDK6 is independent of cyclin D3 
expression.
Lack of cyclin D3 reduces keratinocyte proliferation and 
increases apoptosis in skin papillomas. The simultaneous 
overexpression of CDK6 and ablation of cyclin D3 led to 
changes in the kinetics of CDK/D-type cyclin complex 
formation, but did not disturb the proliferative status of mouse 
keratinocytes (Fig. 3). To investigate the biological deter-
minants responsible for the reduced number of papillomas 
observed upon variation in the levels of CDK6 and cyclin D3, 
the authors monitored possible alterations in proliferation and 
apoptosis.
On the last day of the study, remaining animals were 
injected with BrdU solution, and tumors were collected 
and preserved in formalin. Paraffin‑embedded tumors were 
immunostained to determine the number of cells in S phase by 
BrdU incorporation analysis. The proliferation status of cyclin 
D3-/- keratinocytes exhibited a 0.5-fold reduction compared 
with wild-type tumors (P<0.05, Bonferroni's multiple 
comparisons test; Fig. 5). By contrast, keratinocyte prolife-
ration increased by 1.5-fold in K5CDK6 and K5CDK6/cyclin 
D3-/- mouse papillomas compared with the wild-type (P<0.05, 
Bonferroni's multiple comparisons test; Fig. 5). Therefore, 
no positive association was observed between the reduced 
papilloma development of cyclin D3-/- and K5CDK6 mice 
and their proliferative status. In order to define whether other 
mechanisms compensate for the changes detected in kerati-
nocyte proliferation, the number of apoptotic keratinocytes 
in papillomas was monitored by TUNEL labeling. Notably, 
papillomas from genetically modified mice exhibited elevated 
apoptosis compared with wild-type tumors (Fig. 6). Consistent 
with a previous study by the authors (36), papillomas from 
K5CDK6 mice displayed a 2.4-fold increase in apoptosis 
compared the wild-type (P<0.05, Bonferroni's multiple 
comparisons test). Likewise, papillomas from cyclin D3-/- and 
K5CDK6/cyclin D3-/- mice exhibited a 2-fold increase in the 
number of apoptotic keratinocytes compared with wild-type 
tumors (P<0.05, Bonferroni's multiple comparisons test; 
Fig. 6). In agreement with these results, a recent study demon-
strated that overexpression of CDK6 and cyclin D1 inhibits cell 
differentiation and causes increased apoptosis (51). The BrdU 
index and the number of apoptotic cells in K5CDK6, cyclin 
D3-/- and K5CDK6/cyclin D3-/- tumors were normalized to the 
corresponding values of wild-type samples (Figs. 5 and 6), 
and the rate of apoptosis/proliferation was calculated for each 
genotype (A/P index). A positive correlation was observed 
between the reduced number of papillomas (multiplicity) and 
the increased apoptotic/proliferation index (Pearson's test, 
P=0.0169; Fig. 6E, A/P index). These results suggest that 
changes in the levels of CDK/D-type cyclin complexes can 
serve a role altering the rate of proliferation and apoptosis 
leading to modifications in the kinetic of mouse skin tumor 
development.
To determine whether modifications in CDK6 and cyclin D3 
levels and the consequent changes in the level of CDK4/cyclin 
Table II. Histopathological analysis of skin tumors.
 Tumor type
 --------------------------------------------------------------------------------------
Mouse genotype Analyzed tumors per group, n Papillomaa, n (%) SCCb, n (%)
Wild-type 21 18 (86) 3 (14)
K5CDK6 20 17 (85) 3 (15)
Cyclin D3-/- 10 10 (100) 0 (0)
K5CDK6/cyclin D3-/- 24 14 (58) 10 (42)
aNo atypia observed in basal layers, basal cell hyperplasia and no invasion of epidermal cells into the dermis. bAtypia in basal and certain 
suprabasal layers. Differentiated or highly undifferentiated premalignant papilloma's and SCC with expansion of basal and spinous layer, loss 
of polarity, and cords of epidermal cells contiguous to the basal layer invading the dermis. SCC, squamous cell carcinoma.
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D1 complexes affect the rate of malignant progression, histo-
pathological analysis of skin papillomas was performed. The 
dysplastic and anaplastic changes that included disturbed cell 
polarity (mainly on the basal cell layer), basal cell hyper-
plasia, disturbed differentiation sequence, increased number 
of mitosis, mitosis in suprabasal layers, abnormal mitosis, 
nuclear hyperchromatism, prominent nucleoli and increased 
nuclear/cytoplasmic ratio were all taken into account. Notably, 
42% of papillomas from K5CDK6/cyclin D3-/- presented 
atypia in basal and certain suprabasal layers and lack of the 
differentiation pattern (intrapapilloma carcinoma and carci-
noma in situ). By contrast, 14-15% of wild-type and K5CDK6 
papillomas displayed areas of intrapapilloma carcinoma, 
whereas all cyclin D3-/- papillomas were regular or moderately 
dysplastic (Table II). These results suggest that the increased 
level of CDK4/cyclin D1 and CDK6/cyclin D1 complexes in 
K5CDK6/cyclin D3-/- mice may be associated with increased 
malignant progression. Supporting this hypothesis, previous 
data demonstrated that increased CDK4/cyclin D1 complexes 
led to increased malignant progression upon the overexpres-
sion of CDK4 in mouse epidermis (25,33).
Discussion
Role of cyclin D3 in epidermal proliferation. Early studies 
by the authors have demonstrated that D-type cyclins are 
differently regulated in mouse epidermis (22,23,27-30). 
Whereas cyclin D1 was upregulated in TPA-induced prolifera-
tive keratinocytes, cyclin D2 and cyclin D3 levels remained 
constant (27). In the present report, it was demonstrated that 
a lack of cyclin D3 expression does not affect keratinocyte 
proliferation. Consistent with this data, cyclin D3-/- and 
wild-type mice exhibited no differences in the total number of 
nucleated keratinocytes in the interfollicular epidermis. More-
over, histological analysis of skin sections revealed no changes 
in the skin structure of cyclin D3-/- mice. Biochemical analysis 
of epidermal lysates revealed an increased level of cyclin D1 
protein and elevated formation of CDK4/cyclin D1 complexes. 
Therefore, epidermal keratinocytes proliferate normally in 
the absence of cyclin D3, likely through the formation of 
CDK4/6-cyclin D1 complexes, as a compensatory mechanism 
due to the lack of CDK4/6-cyclin D3 complexes. Although 
a lack of cyclin D3 expression does not alter the apoptotic 
Figure 5. Cyclin D3 ablation reduces keratinocyte proliferation in skin papillomas. BrdU incorporation in papillomas from (A) WT, (B) K5CDK6, (C) D3 KO, 
and (D) K5CDK6/D3 KO mice. Magnification, x400. (E) Quantification of BrdU‑positive cells in skin papillomas (BrdU label index) shows reduced prolifera-
tion in D3 KO tumors compared with WT papillomas (*P<0.05 D3 KO vs. wild-type controls, one-way ANOVA and Bonferroni's multiple comparisons test). 
Increased proliferation of K5CDK6 and K5CDK6/D3KO tumors compared with WT papillomas (**P<0.05, K5CDK6 vs. wild-type controls and ***P<0.05, 
K5CDK6/D3KO vs. wild-type controls; one-way ANOVA and Bonferroni's multiple comparisons test). BrdU, bromodeoxyuridine; WT, wild-type; KO, 
knockout.
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index in the interfollicular epidermis, a relevant increase was 
observed in the number of apoptotic keratinocytes in the bulge 
area of the hair follicles. These results suggest that a lack of 
cyclin D3 expression affects the long-lived epithelial stem cells 
located within the bulge region. Fate-mapping experiments 
have demonstrated that these cells do not normally contribute 
to epidermal homeostasis (45), which explains why a lack of 
cyclin D3 does not affect the normal structure of epidermis. 
However, apoptosis in the bulge area of the hair follicle may 
affect re-epithelialization following wounding as epithelial 
injury leads to the recruitment of bulge-derived keratinocytes 
into the epidermis (45). Early studies by the authors and the 
results presented throughout this report demonstrated that the 
molecular mechanisms leading to compensatory changes in 
D‑type cyclin levels respond only to modifications in cyclin 
D3, but not cyclin D1 or cyclin D2 (29,50). In fact, transgenic 
expression of cyclin D3 is compensated by a reduction in levels 
of cyclin D2 (50), whereas a lack of cyclin D3 is compensated 
by overexpression of cyclin D1 (Fig. 3). The authors conclude 
that changes in the expression of cyclin D3 does not affect 
epidermal homeostasis, due to compensatory mechanisms 
by other members of the D-type cyclin family. However, 
increased levels of cyclin D1/cdk4 in cyclin D3-/- epidermis led 
to hair follicle apoptosis in the bulge area, similar to results 
observed in retinoblastoma-null mice (40).
Cyclin D3 in skin tumorigenesis. The authors have previ-
ously reported that overexpression and ablation of D-type 
cyclins results in varied sensitivities to chemically induced 
mouse skin papillomas (29,30,52,53). By using the two-stage 
carcinogenesis model, genetic evidence that ras-mediated 
skin tumor development depends on signaling pathways that 
act preferentially through cyclin D1 and cyclin D2 has been 
provided (28,29,35). However, the role of cyclin D3 in skin 
carcinogenesis has not yet been defined. Substantial evidence 
has suggested that cells from the bulge area of hair follicles 
have characteristics similar to stem cells, including slow 
cycling, label-retaining properties and a high proliferative 
capacity (54-56). In this regard, Morris et al (47) demonstrated 
that bulge-area stem cells (BuSCs) retain carcinogen-DNA 
adducts, which supports the idea that these cells are targeted 
during chemical initiation (47,57). The number of skin 
Figure 6. Increased apoptosis in skin papillomas from cyclin D3-/-, K5CDK6 and K5CDK6/cyclin D3-/- mice. Apoptotic cells were visualized by terminal deoxy-
nucleotidyl transferase dUTP nick end labeling assay in papillomas from (A) WT, (B) K5CDK6, (C) D3 KO, and (D) K5CDK6/D3 KO mice. Magnification, 
x400. (E) Increased apoptosis in keratinocytes from K5CDK6, D3 KO, and K5CDK6/D3 KO tumors compared with WT papillomas (*P<0.05, K5CDK6 
vs. wild-type controls, **P<0.05, D3 KO vs. wild-type controls, and ***P<0.05, K5CDK6/D3KO vs. wild-type controls; one-way ANOVA and Bonferroni's 
multiple comparisons test), n=10 per group. The number of apoptotic cells and BrdU index were normalized to the wild-type samples, and the rate of apop-
tosis/proli feration was calculated (A/P Index). WT, wild-type; D3 KO, cyclin D3-/- mice; K5CDK6/D3 KO, K5CDK6/cyclin D3-/- mice.
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papillomas is associated with the number of initiated cells 
and/or other early events, including the clonal expansion of 
initiated cells. It was observed that cyclin D3 deletion and 
CDK6 overexpression (36) resulted in an increased number 
of hair follicles bearing apoptotic cells in the bulge region. 
Therefore, the authors hypothesized that cyclin D3 ablation 
leads to a reduced number of initiated cells and decreased skin 
papilloma development. To test this hypothesis, the two-stage 
carcinogenesis protocol was used, which allowed for study 
of the effect of cyclin D3 ablation during tumor initiation (an 
irreversible genetic alteration in a target cell), promotion (the 
process by which an initiated tissue develops focal prolifera-
tion leading to clonogenic expansion of the initiated cells), and 
malignant progression to SCC (the final transition to invasive 
behavior) (58). Supporting the hypothesis, a relevant reduc-
tion in multiplicity and incidence of papillomas was observed 
in cyclin D3-null mice compared with wild-type mice. 
Furthermore, 50% of cyclin D3-/- mice remained refractory to 
papilloma development (Figs. 2 and 4). These results provide 
genetic evidence that a lack of cyclin D3 expression and a 
further increase in apoptosis in the bulge region of the hair 
follicle, affects the number of initiated cells or, alternatively, 
the clonal expansion of the initiated cells. Similarly, ablation of 
cyclin D1, cyclin D2, CDK4 and Skp2 led to a reduced number 
of papillomas due to failure during the initiation or early 
promotion stages (28,29,32–34,36). Likewise, overexpression 
of CDK6 resulted in increased apoptosis in the bulge region of 
the hair follicle and inhibition of papilloma development (36).
The fact that cyclin D3 preferentially binds to CDK6 in 
mouse keratinocytes (27,36) led to the hypothesis that the 
inhibitory action of CDK6 depends on cyclin D3. To test this 
hypothesis, K5CK6/cyclin D3-/- compound mice were genera ted 
and subjected to a two-stage carcinogenesis protocol. Contrary 
to the hypothesis, the inhibition of papilloma formation driven 
by CDK6 expression and a lack of cyclin D3 did not act in a 
linear fashion, since a lack of cyclin D3 expression did not 
affect the tumor-repressing activity of CDK6. Cyclin D3 abla-
tion resulted in the most substantial tumor inhibition, when 
compared with K5CDK6 and K5CDK6/cyclin D3-/- mice. 
The authors speculate that forced expression of CDK6 and 
increased formation of CDK6/cyclin D1 and CDK6/cyclin D3 
complexes played a positive role during the clonal expansion of 
initiated cells in K5CDK6 and K5CDK6/D3-/- mice, but not in 
cyclin D3-/- mice. Supporting this view, CDK6/cyclin D3 and 
CDK6/cyclin D1 showed a faster kinetic of complex formation 
upon TPA treatment on mouse epidermis, compared with other 
D-type cyclin/CDKs complexes (27). The molecular mecha-
nisms by which alterations in the kinetics of CDK/D-type 
cyclin complex formation affects the clonogenic expansion of 
the initiated cells remains unclear and is beyond the scope of 
the present study. Similar to the cyclin D3-/- model, ablation of 
Rb, the primary substrate of CDK4 and CDK6, in the mouse 
epidermis also resulted in increased apoptosis and a reduction 
in the number of papillomas (40). Altogether, the results of the 
present study and from the epidermal‑specific Rb-/- mice (40) 
support a model in which the phosphorylation/inactivation of 
Rb by elevated CDK activity leads to apoptosis in BuSCs with 
the consequent reduction in the number of skin papillomas. 
The likelihood that CDKs and/or D-type cyclins exert their 
tumor inhibitory effect through Rb-independent mechanisms 
cannot be ruled out. In this regard, it has been reported that 
CDK6 is part of a transcription complex that induces the 
expression of the tumor suppressor p16Ink4 (59). Whether this 
kinase-independent function of CDK6 is active in keratinocytes 
and BuSCs is unknown. However, the authors hypothesize 
that downregulation of D-type cyclins results in elevation 
of the free-CDK6 and its transcription activity, leading to 
the blockage of the expansion of initiated cells via p16Ink4a 
transcription. In the last 5 years, a number of non-canonical 
functions of D-type cyclins as transcription factors have been 
described (60,61). For instance, the transcription factor Runx1 
is negatively regulated by cyclin D3 in a kinase-independent 
manner (62). Runx1 promotes the proliferation of hair follicle 
stem cells and induces epithelial tumor formation in mouse 
skin (63). Therefore, a lack of and/or overexpression of cyclin 
D3 may unbalance the apoptotic/proliferative rate in BuSCs, 
with a direct impact on the rate of tumor formation.
Histopathological analysis of skin tumors indicated that 
simultaneous overexpression of CDK6 and a lack of cyclin D3 
expression resulted in an increased rate of malignant progression. 
The K5CDK6/D3-/- mice developed more aggressive tumors and 
42% were classified as premalignant papillomas or SCC, whereas 
only 15% of K5CDK6 and 14% of wild-type tumors exhibited 
similar characteristics (Table II). Cyclin D3-/- tumors were clas-
sified as regular papillomas with no atypia in the basal layers 
and no invasion of epidermis cells into the dermis. Biochemical 
analysis of epidermal lysates from K5CDK6/cyclin D3-/- mice 
revealed elevated levels of CDK6/cyclin D1 and CDK4/cyclin 
D1 complexes, whereas cyclin D3-/- epidermis only displayed 
elevated levels of CDK4/cyclin D1 complexes (Table I). Simi-
larly, it has been previously reported that increased CDK4 
expression in K5CDK4 transgenic mice induces malignant 
progression of skin papillomas (25,44). Notably, the malignant 
progression observed in K5CDK4 mice was partially mediated 
via p27Kip1 sequestration by the CDK/cyclin complexes and 
the indirect activation of CDK2 (25,44). Therefore, data of the 
present study suggest that the simultaneous increase in the level 
of CDK4/cyclin D1 and CDK6/cyclin D1 complexes observed 
in K5CDK6/cyclin D3-/- mice may result in CDK2 activation, 
leading to increased malignant progression.
Collectively, the results of the present study indicate that the 
absence of cyclin D3 leads to decreased papilloma formation in 
mouse epidermis due to increase apoptosis in the bulge region 
of the hair follicle. These observations indicate that regulation 
of cell survival of BuSC is a crucial mechanism for crippling 
cellular defense against neoplasia. The data of the present 
study suggest that cyclin D3 inhibition blocks an early event 
of the multistage process of non-melanoma skin tumorigen-
esis. Although cyclin D3 binds preferentially to CDK6 (27), 
the tumor inhibition mediated by CDK6 is independent of 
cyclin D3. Finally, the present study indicates that the unbala-
nced formation of CDK4/6-D-type cyclin complexes leads 
to reduced papilloma development and may result in a more 
aggressive tumor phenotype, increasing malignant progression.
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